TrialBMC medicine2025

Efficacy and safety of Janus kinase 1/2 inhibitor KL130008 in active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase II trial.

Yue Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.